+ More Filters

Reset Filters

Title

Funding Organization

Funding Type

Eligible Country

Deadline

Other (Select all that apply)

Show Expired Programs

Show Verified Programs

Verified

Wong Family Foundation Research Award

TSC Alliance

The TSC Alliance is dedicated to creating a future where everyone affected by tuberous sclerosis complex (TSC) can live their fullest lives. We invest in early-career researchers to drive innovative TSC research and to foster a diverse group of researchers dedicated to our shared mission. In 2024, we anticipate awarding three or four awards to postdoctoral fellows and early-stage investigators depending on merit, requested budgets, and funds available. A description of research funded previously is available on the TSC Alliance

Thanks to generous support from the Wong Family Foundation, the TSC Alliance is proud to again offer this special funding opportunity as part of our regular research grant and postdoctoral fellowship cycle. This two-year award will be designated to the most meritorious application focusing on epilepsy research. All epilepsy-focused Postdoctoral Fellowship and Research Grant candidates will automatically be considered for the Wong Family Foundation Research Award, so no additional information is required during the application process.

Areas of emphasis for a project designated the Wong Family Foundation Research Award may include (but are not limited to):
- Basic research in mechanisms relating to intractability, e.g., multi-drug resistant epilepsy
- Model development (especially for infantile spasms or intractable epilepsy)
- New technologies related to epilepsy (imaging, electrophysiology, etc.)

Award Budget and Project Period

All Applicants

• The maximum project period is two years. The project period may be shorter if appropriate for the project.

• The maximum total costs are $75,000 per year and $150,000 total, inclusive of both direct and indirect costs.

• Indirect costs may not exceed 10% of the total cost ($7,500 per year or $15,000 total).

• Up to $2,000 total may be allotted toward travel expenses to support the applicant’s professional development.

AI Based Application Success Predictor

Based on funding priorities and research trends:

🥇 1. Direct Relevance to TSC (Top Predictor)

Must clearly address:
- TSC biology
- Symptoms (epilepsy, tumors, neurodevelopmental issues)

✔ Strong disease focus is mandatory

🥈 2. Therapeutic Development Potential

Highest priority:
- Projects leading to new treatments

✔ High success:

Drug development
Clinical trials

🥉 3. Translational Impact

Preference for:
- Bench-to-bedside research

✔ Projects with clinical applicability perform best

4. Mechanistic Understanding (mTOR Pathway Focus)

Strong emphasis on:
- Molecular mechanisms

✔ Especially:

TSC1/TSC2 mutations
mTOR signaling

5. Use of Patient Data / Clinical Cohorts

Preferred:
- Registries
- Clinical datasets

6. Feasibility & Milestone-Based Design

Typically:
- Structured funding

✔ Requires:

Clear deliverables

7. Collaboration (Multicenter Advantage)

Strong proposals involve:
- Clinical networks
- Multiple institutions

8. Innovation in Rare Disease Research

Competitive proposals include:
- Novel targets
- Precision medicine approaches

🧪 Common Funded Research Areas

Epilepsy in TSC
mTOR pathway and targeted therapies
Neurodevelopmental disorders (autism, cognition)
Tumor biology (renal, brain lesions)
Biomarkers and imaging
Clinical trials

⚠️ Common Reasons for Rejection

Weak relevance to TSC
Lack of therapeutic focus
Pure basic research without translation
Poor feasibility
No clear patient impact

🧠 Bottom Line (Key Predictors Ranked)

Direct relevance to TSC
Therapeutic development potential
Translational/clinical impact
Mechanistic insight (mTOR focus)
Feasible, milestone-driven design
Collaboration and clinical data use

✔️ In short:
TSC Alliance funding favors translational, therapy-focused research aimed at improving treatment and outcomes for TSC patients.

Specialties

Clinical Trials

Neurosciences

Eligibility Requirements

• All applicants must have a doctoral-level degree, e.g., MD or PhD or equivalent.

• All applicants must meet the NIH definition of an early-stage investigator (ESI) as of the LOI due date. An ESI is a Principal Investigator (PI) who has completed his or her terminal research degree or end of post-graduate clinical training, whichever date is later, within the past 10 years and who has not previously competed successfully as a Program Director (PD) or PI for a substantial NIH independent research award. A list of NIH grants that a PD/PI can hold and still be considered an ESI can be found at: https://grants.nih.gov/policy/early-investigators/list-smaller-grants.htm

• All applicants must be investigators at established academic or research institutions or at pharmaceutical or biotechnology companies worldwide. Researchers residing in the United States who are not US citizens are eligible to apply.

Sponsor Details

Sponsor Institute/Organizations: TSC Alliance

Sponsor Type: Corporate/Non-Profit

Address: 8737 Colesville Road, Suite 400 Silver Spring, Maryland

Legal & Affiliation Disclaimer

Affiliation Disclaimer: Trialect operates independently and is not affiliated with, endorsed by, or supported by any sponsors or organizations posting on the GrantsBoard platform. As an independent aggregator of publicly available funding opportunities, Trialect provides equal access to information for all users without endorsing any specific funding source, content, organization, or sponsor. Trialect assumes no responsibility for the content posted by sponsors or third parties.

Subscription Disclaimer: Upon logging into Trialect, you may choose to SUBSCRIBE to GrantsBoard for timely notifications of funding opportunities and to access exclusive benefits, such as priority alerts, reminders, personalized recommendations, and additional application support. However, users are advised to contact sponsors directly for any questions and are not required to subscribe to engage with funding opportunities.

Content Ownership and Copyright Disclaimer: Trialect respects the intellectual property rights of all organizations and individuals. All content posted on GrantsBoard is provided solely for informational purposes and remains the property of the original owners. Trialect does not claim ownership of, nor does it have any proprietary interest in, content provided by third-party sponsors. Users are encouraged to verify content and ownership directly with the posting sponsor.

Fair Use Disclaimer: The information and content available on GrantsBoard are compiled from publicly accessible sources in alignment with fair use principles under U.S. copyright law. Trialect serves as an aggregator of this content, offering it to users in good faith and with the understanding that it is available for public dissemination. Any organization or individual who believes their intellectual property rights have been violated is encouraged to contact us for prompt resolution.

Third-Party Posting Responsibility Disclaimer: Trialect is a neutral platform that allows third-party sponsors to post funding opportunities for informational purposes only. Sponsors are solely responsible for ensuring that their postings comply with copyright, trademark, and other intellectual property laws. Trialect assumes no liability for any copyright or intellectual property infringements in third-party content and will take appropriate action to address any substantiated claims.

Accuracy and Verification Disclaimer: Trialect makes no warranties regarding the accuracy, completeness, or reliability of the information provided by sponsors. Users are advised to verify the details of any funding opportunity directly with the sponsor before taking action. Trialect cannot be held liable for any discrepancies, omissions, or inaccuracies in third-party postings.

Notice and Takedown Policy: Trialect is committed to upholding copyright law and protecting the rights of intellectual property owners. If you believe that content on GrantsBoard infringes your copyright or intellectual property rights, please contact us with detailed information about the claim. Upon receipt of a valid notice, Trialect will promptly investigate and, where appropriate, remove or disable access to the infringing content.

View Funding Opportunity